Shriram Finance shares were in demand as the financial services major reported strong growth in interest income and also reported better than expected quarterly numbers.
Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).
Prabhudas Lilladher has reaffirmed its BUY recommendation on Cipla, driven by the company's strong financial performance and strategic growth initiatives.
Geojit Financial Services has reaffirmed its BUY recommendation for Cipla Ltd., assigning a revised target price of Rs. 1,695. This valuation is based on a 26x FY26E adjusted EPS.
